- Research article
- Open Access
Type three secretion system-mediated escape of Burkholderia pseudomallei into the host cytosol is critical for the activation of NFκB
© Teh et al.; licensee BioMed Central Ltd. 2014
- Received: 30 December 2013
- Accepted: 25 April 2014
- Published: 6 May 2014
Burkholderia pseudomallei is the causative agent of melioidosis, a potentially fatal disease endemic in Southeast Asia and Northern Australia. This Gram-negative pathogen possesses numerous virulence factors including three “injection type” type three secretion systems (T3SSs). B. pseudomallei has been shown to activate NFκB in HEK293T cells in a Toll-like receptor and MyD88 independent manner that requires T3SS gene cluster 3 (T3SS3 or T3SSBsa). However, the mechanism of how T3SS3 contributes to NFκB activation is unknown.
Known T3SS3 effectors are not responsible for NFκB activation. Furthermore, T3SS3-null mutants are able to activate NFκB almost to the same extent as wildtype bacteria at late time points of infection, corresponding to delayed escape into the cytosol. NFκB activation also occurs when bacteria are delivered directly into the cytosol by photothermal nanoblade injection.
T3SS3 does not directly activate NFκB but facilitates bacterial escape into the cytosol where the host is able to sense the presence of the pathogen through cytosolic sensors leading to NFκB activation.
- HEK293T Cell
- Endosome Escape
- Burkholderia Pseudomallei
- T3SS3 Effector
Burkholderia pseudomallei, the causative agent of melioidosis, is a highly versatile Gram-negative bacterium capable of invading epithelial cells  as well as surviving in macrophages . Common routes of entry for B. pseudomallei are via cutaneous inoculation, inhalation, or ingestion. Melioidosis is endemic in Southeast Asia, Northern Australia and other tropical regions , and clinical outcome is relatively dependent on the size of the inoculum and the existence of predisposing risk factors . B. pseudomallei possesses an extensive arsenal of recognized virulence determinants, including three “injection type” type III secretion systems (T3SSs) and six type VI secretion systems (T6SSs). T3SSs are present in many Gram-negative pathogens and translocate “effector” proteins into eukaryotic host cells to alter their cellular response. In B. pseudomallei, only T3SS3 has been implicated in animal pathogenesis [5, 6], while T3SS1 and −2 are predicted to mediate interactions with plants . T3SS3 has also been shown to be important for bacterial escape from phagosomes or endosomes into the host cytosol [8, 9] and caspase 1-induced pyroptosis .
Since T3SS is a virulence determinant utilized by a variety of Gram-negative species, mammalian hosts have evolved sensors to detect the presence of T3SSs during pathogenesis. In macrophages, the T3SS of Salmonella typhimurium, Shigella flexneri, B. pseudomallei, Pseudomonas aeruginosa, enterohemorrhagic and enteropathogenic E. coli trigger a proinflammatory response mediated by the NLRC4 inflammasome and subsequent activation of caspase 1 . In Yersinia, it is unclear whether caspase 1 activation is triggered by the translocon pore or via unknown T3SS-related factors . In addition to detection by the inflammasome machinery, Yersinia and Salmonella can be detected by NFκB in a Toll-like receptor (TLR) and MyD88 independent manner that is reliant on T3SS, revealing another possible mechanism whereby T3SS can be detected by host epithelial cells which lack inflammasome machinery. Using human embryonic kidney cells (HEK293T), which are epithelial cells that lack TLR 2, 4 and 9 expression but expresses low levels of TLR5 and 7 [15, 16], we have previously shown that B. pseudomallei stimulates NFκB independently of TLRs and MyD88, leading to the production of IL-8. NFκB activation required bacterial internalization and a functional T3SS3 . However, it is unclear whether NFκB activation is triggered by T3SS3 effector proteins, by components of the T3SS secretion apparatus itself, or indirectly via additional T3SS3-mediated processes.
Our goal is to determine how T3SS3 contributes to NFκB activation in the absence of TLR, MyD88 and inflammasome signalling using HEK293T epithelial cells as a model system. We show that T3SS3-mediated endosome escape is required for NFκB activation and occurs independently of known T3SS3 effector proteins. Using a photothermal nanoblade to directly place bacteria into the cytoplasm, we show that cytosolic localization is sufficient to activate NFκB. Thus, B. pseudomallei T3SS3 is not directly detected by the host NFκB pathway but is instead responsible for bacterial escape from vacuolar compartments subsequently leading to the activation of cytosolic sensors.
TLR-independent NFκB activation by B. pseudomallei is dependent on the activity of T3SS3 but not known T3SS3 effector proteins
T3SS3 does not facilitate invasion of bacteria into cells but rather promotes their subsequent escape from endocytic vesicles . Therefore, defective endosome escape by mutants may provide an explanation for their reduced replication and inability to activate NFκB. Thus, we examined whether the ability of these mutants to activate NFκB correlate with their ability to escape from the endosome. The formation of multinucleated giant cells (MNGC) at 10–12 hr. following infection was utilized as a measure of endosome escape, since it requires the activity of T6SS1 and only occurs if bacteria have escaped from endocytic vesicles into the cytosol [18, 24]. We examined the formation of MNGC at 12 hr. post infection of the single and triple effector mutants in comparison with wildtype KHW and the escape-deficient ΔbsaM (Figure 2C). All strains could induce MNGC at this time-point except for ΔbsaM, indicating that the ability to activate NFκB correlates with the ability to escape. ΔbopACE formed less MNGCs compared to the rest, likely reflecting its lower replication ability.
T3SS3 mutants activate NFκB when they gain access to the host cytosol
If NFκB activation at early time points results from rapid escape from the endosome, then direct placement of bacteria into the cytosol should obviate the need for T3SS-mediated escape. This was tested using a photothermal nanoblade, which allows us to bypass the need for invasion and endosome escape altogether [24, 26]. The photothermal nanoblade utilizes a 6 ns pulse from a 540 nm laser to excite a titanium coating on glass micropipettes that are brought into contact with mammalian cell membranes. Rapid heating results in the formation of a vapour “nanobubble”, creating a local, transient delivery portal in the membrane bilayer through which cargo can be introduced. The advantages of photothermal nanoblade compared to traditional microinjection are that variably-sized particles – from molecules to bacteria - can be efficiently delivered into a wide range of cell types, and cell viability is maintained since physical puncturing does not occur.
B. pseudomallei stimulates activation of endogenous NFκB in HEK293T cells
Several Gram-negative bacterial pathogens capable of infecting epithelial cells possess secretion systems such as T3SS or T4SS that modulate NFκB signalling. In Legionella pneumophila, NFκB activation was shown to occur via a TLR dependent pathway, as well as a TLR-independent pathway that requires the Icm/Dot translocation system [29–32]. Recently, a Icm/Dot substrate LnaB has been identified to be responsible for TLR-independent activation of NFκB with activation of RIP2 (common downstream intermediate of NOD1 and NOD2) in HEK293T cells . Another T4SS secreted effector, LegK1, activates NFκB directly by phosphorylating NFκB inhibitor IκBα, leading to downstream activation independent of host PRRs .
Intestinal pathogens such as Salmonella and Shigella have been shown to activate NFκB in intestinal epithelial cells in a TLR independent manner. For example, Shigella flexneri invades and activates NOD1, which senses bacterial peptidoglycan, leading to IL-8 production . In Salmonella, the T3SS effector SopE activates NFκB  by engaging small Rho GTPases CDC42 and Rac1, which in turn trigger NOD1 and RIP2 activation of NFκB . Another Salmonella T3SS effector protein SipA was also found to activate NFκB via NOD1/NOD2 signalling pathway that proceeds through RIP2 . In contrast, it cannot be definitively determined in Yersinia whether the T3SS cargo or translocon pore is responsible for activating NFκB .
In this study, we have shown that B. pseudomallei and B. thailandensis T3SS3 do not directly activate NFκB in any significant way in HEK293T epithelial cells. T3SS3 is necessary for efficient escape of bacteria from endosomal/phagosomal compartments into the cytosol at early time-points, although some escape may occur with low efficiency at later time-points independently of T3SS3 . Although the direct delivery of T3SS3 mutants was done only with B. thailandensis, the time course of MNGC formation and NFκB activation of B. pseudomallei ∆bsaM mutants, and the similarity in various parameters between the two species in our experiments as well as what has been reported in the literature [23, 26] would support our conclusion. In contrast to what has been found for Salmonella, known T3SS3 effectors are not essential for NFκB activation by Burkholderia. This is supported by several lines of evidence: T3SS mutant bacteria exhibit delayed but significant NFκB activation at later time-points, corresponding to their escape into the cytosol; overexpressed T3SS3 effectors do not activate NFκB; and direct delivery of bacteria into the cytosol via nanoblade injection obviates the need for T3SS3 in NFκB activation even at early time-points. Thus, the key event triggering NFκB activation is the presence of Burkholderia in the cytoplasm. We have not completely ruled out the possibility that unknown T3SS3 effectors secreted by other T3SSs in the absence of T3SS3 may partly be responsible for the NFκB activation we see, but even if this is true, it likely plays a minor role as the activation would not have depended so much on the cytosolic presence of the bacteria. The requirement for cytosolic presence of the pathogen likely reflects the host’s reliance on cytosolic sensors to detect generic pathogen associated molecular patterns (PAMPs) rather than the specific recognition of T3SS- or T4SS-associated proteins as seen for pathogens that depend on survival within a vacuolar compartment such as Salmonella and Legionella. However, we cannot rule out the possibility that the cytosolic presence of bacteria expose T3SS3 structural components to activate NFκB.
The detection of endogenous TAK1 activation in HEK293T cells following infection with wildtype, but not T3SS3 mutants, suggests the activation of the intracellular pattern recognition receptors (PRRs) NOD1 and NOD2, both of which signal through TAK1. B. pseudomallei is reportedly able to signal through NOD2 in RAW264.7 macrophages to upregulate suppressor of cytokine signalling 3 (SOCS3) although it does not result in similar upregulation of the proinflammatory cytokines TNFα, IL-1β and IL-6 which depend on activation of NFκB . Recently, it is reported that NOD2 plays a minor role in murine melioidosis and a human genetic polymorphism in NOD2 region is associated with melioidosis . It is possible that NOD1 and NOD2, which sense bacterial peptidoglycan derivatives IE-DAP and muramyl dipeptide respectively, may be the major cytosolic sensors responsible for NFκB activation.
Use of the HEK293T cells has allowed us to determine how Burkholderia T3SS3 contributes to NFκB activation in the absence of TLR and MyD88 signalling. We were able to discern that activation of NFκB does not occur as a direct consequence of Burkholderia T3SS3 secretion of effectors, but rather through cytosolic sensors that respond to the presence of bacteria in the cytosol following T3SS3-mediated escape from endocytic vesicles. Our study serves as a model for future work to identify the cytosolic sensors and the conditions leading to NFκB activation. It is possible that NFκB is not triggered efficiently by surface or endosomal PRRs, whereupon cytosolic sensors become important in establishing recognition of bacterial pathogens and eventual protection. Alternatively, the activation of these cytosolic sensors may lead to a different gene expression program that provides a regulatory function distinct from the TLR response.
Cell-lines and bacterial strains
List of bacterial strains used in this study
Relevant characteristic(s) a
Source or reference
B. pseudomallei wildtype strain
T3SS1 cluster was replaced with tetracycline resistance gene, Tcr
T3SS2 cluster was replaced with tetracycline resistance gene, Tcr
T3SS3 cluster was replaced with zeocin gene, Zeor
bsaM orf was deleted
bopA orf was replaced with zeocin resistance gene, Zeor
bopC orf was replaced with zeocin resistance gene, Zeor
bopE orf was deleted
bopA and bopE orfs were deleted, bopC orf was replaced with zeocin resistance gene, Zeor
B. thailandensis wildtype strain
bsaS orf was deleted
bsaM orf was deleted
Bacterial mutant construction
Plasmids used for cellular transfection in the study
Relevant characteristic(s) a
Source or reference
Conjugative, suicide vector containing sacB gene, Kmr
Source of zeocin resistance gene, Apr, Zeor
Reporter vector containing NFκB enhancer element fused to SEAP gene, AmpR
Expression Vector, AmpR
Expression Vector, AmpR
bopA gene cloned into pcDNA3.1/V5-His TOPO by TA-cloning, AmpR
bopC gene cloned into pCMV-FLAG-MAT-Tag-1, AmpR
bopE gene cloned into pRK5myc, AmpR
sopE gene cloned into pRK5myc, AmpR
List of primers for this study
BsaM up for
BsaM up rev
BsaM dn for
BsaM dn rev
BopA up for
BopA up rev
BopA dn for
BopA dn rev
BopC up for
BopC up rev
BopC dn for
BopC dn rev
BopE up for
BopE up rev
BopE dn for
BopE dn rev
Bt BsaM up for
Bt BsaM up rev
Bt BsaM dn for
Bt BsaM dn rev
Expression in mammalian cells
BopA RT for
BopA RT rev
BopC RT for
BopC RT rev
BopE RT for
BopE RT rev
Plasmid transfection and NFκB reporter assay
HEK293T cells were seeded at a density of 1.25x105 cells/well in 24-well tissue culture plates and incubated for 24 hr. For measuring the activation of NFκB by B. pseudomallei wildtype (KHW) and mutants, the cells were transfected with 100 ng of pNFκB -SEAP plasmid using jetPRIME DNA & siRNA transfection reagent (Polyplus Transfection). After another 24 hr., the media were replaced with antibiotics-free media. The cells were then infected with mid log-phase cultures of B. pseudomallei at required MOI. Following infection, plates were centrifuged at 200 x g for 5 min to allow maximum bacteria to cell contact. Two hr. post infection, 250 μg/ml kanamycin was added to kill off extracellular bacteria. Cells without infection were included as control. Supernatant was collected at various time points and SEAP activity was measured. For measuring the activation of NFκB by B. pseudomallei T3SS3 effectors, the cells were co-transfected with 100 ng of pNFκB -SEAP plasmid and up to 400 ng of plasmid harbouring B. pseudomallei T3SS3 effector gene or 400 ng of empty plasmid using jetPRIME DNA & siRNA transfection reagent. Total amount of DNA transfected were kept constant at 500 ng. After another 24 hr., supernatant was collected and SEAP activity was measured. SEAP activity was measured using Phospha-Light kit (Life Technologies) according to the instructions of the manufacturer. Relative NFκB activation was calculated by averaging the raw luminescence values obtained using the Phospha-Light kit and converting them to fold activation with respect to uninfected cells or cells transfected with empty vector.
Intracellular bacterial count
HEK293T cells were seeded and infected as described above. Two hr. post infection, cells were washed twice with 1x PBS before addition of fresh culture medium with 250 μg/ml kanamycin. At respective time points, infected cells were washed with 1x PBS and lysed with 0.1% (v/v) Triton X-100. Serial dilutions were performed on the lysates and subsequently plated on TSA agar and incubated at 37°C for 48 hr. Colony counts were used to calculate bacterial loads.
Cytotoxicity of B. pseudomallei against HEK293T cells
HEK293T cells (1.25 x 105 cells/well) were seeded and grown overnight in a 24 well plate. Cells were infected with the indicated MOI. At 1 hour post infection, kanamycin (250 μg/ml) was added to kill extracellular bacteria. Cytotoxicity was measured at 6 hr. post infection by assaying for lactate dehydrogenase (LDH) release in the cell supernatants using a LDH Cytotoxity Detection Kit (Clontech).
Multi-nucleated giant cell assay
HEK293T cells were seeded at a density of 2.5 x 104 cells/well in a 24-well tissue culture plate and infected with log-phase bacteria at MOI 10:1. Two hr. post infection, kanamycin was added to kill off extracellular bacteria and at respective time points, cells were washed with 1xPBS and fixed with 100 % methanol (Sigma-Aldrich) for 1 min. Cells were then rinsed with water and air dried before the addition of 20x diluted Giemsa stain (Sigma-Aldrich) for 20 min. After staining, cells were washed with water two times before they were air dried and examined under light microscope for MNGC formation.
Cloning of full-length bopA, and bopC gene into mammalian expression vector
The pcDNA3.1/V5-His TOPO (pcDNA3.1) TA Expression kit (Life Technologies) was used for cloning of full-length bopA for over-expression in mammalian systems. The bopA coding sequence including stop codon was included in the primer so that the products were not tagged. Amplified product was cloned into the linearized pcDNA3.1 vector according to manufacturer’s protocol. The bopC was cloned into pCMV-FLAG-MAT-Tag-1 Expression Vector (Sigma) according to manufacturer’s instruction. The primers for amplification of bopA and bopC are listed in Table 3.
Measurement of B. pseudomallei effector gene expression by real-time PCR
Total RNA was isolated from transfected HEK293T cells 24 hours post transfection using illustra RNAspin Mini Kit (GE Healthcare). cDNA was synthesized using 1 μg of RNA and the First Strand cDNA Synthesis Kit (Thermo Scientific). Transcripts were quantified using iQ Cybr Green Supermix (Bio-Rad) in a Bio-Rad iQ5 machine. The expression of effector gene was normalized to housekeeping control gene gapdh. Real-time PCR primers are listed in Table 3.
Photothermal nanoblade delivery of bacteria
Bacteria for photothermal nanoblade injection were prepared by culturing in low-salt L- broth at pH 5.8 until log-phase and then washed 3X and resuspended in Hanks balanced salt solution (HBSS) at 108–109 cfu/mL. 1–2 μl of the bacterial suspension was loaded into titanium-coated pulled-glass microcapillary pipettes. Photothermal nanoblade delivery was performed essentially as described [24, 26]. Briefly, the pulsed laser system used was a Q-switched, frequency-doubled Nd:YAG laser (Minilite I, Continuum) operated at 532 nm wavelength and 6 ns pulsewidth. The laser beam was sent into the fluorescence port of an inverted microscope (AxioObserver, Zeiss) and then through the objective lens (40X, 0.6 NA), to generate a 260 μm-wide laser spot on the sample plane. The optimized laser intensity used for bacterial delivery was 180 mJ/cm2. The excitation laser pulse was synchronized with a liquid delivery system (FemtoJet, Eppendorf) using an electronic switch. A pressure of 100–350 hPa was used to deliver 1–2 pl of suspension per pulse. Approximately one bacterium was successfully delivered into a cell every two pulses. Following nanoblade delivery, cells were washed twice with HBSS before the addition of fresh medium with 250 μg/mL kanamycin [24, 26].
HEK293T cells were first seeded in a 6 well plate at a density of 1 x 106 cells per well and then infected with the required strain the following day. At required time points, cells were lysed with lysis buffer (50 mM Tris pH 7.5, 0.1 mM EGTA, 0.27 M sucrose, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM sodium pyrophosphate, 1% Triton-100, protease inhibitor cocktail). Protein G sepharose beads (Sigma-Aldrich) were pre-incubated with total TAK1 antibody (kind gift from Dr. Peter Cheung, Nanyang Technological University, Singapore) before the cell lysates were mixed and incubated with the beads for 1 hr. at 4°C with shaking. Beads were then washed twice with lysis buffer and twice with wash buffer (50 mM Tris–HCl pH 7.5, 0.27 M Sucrose, 0.1% 2-mercaptoethanol) before being boiled in SDS-PAGE sample buffer. Samples were subsequently resolved on SDS-PAGE gels and transferred onto nitrocellulose membrane (Pall Life Sciences).
Cells were lysed with MPer mammalian protein extraction reagent (Thermo Scientific) supplemented with protease cocktail (Thermo Scientific). Proteins were then quantitated using Bradford reagent (Bio-Rad). Samples were boiled in SDS-PAGE sample buffer and 50 μg (per lane) were resolved on an SDS-PAGE gel and transferred onto nitrocellulose membranes (Pall Life Sciences). The membranes were then blocked with 5% BSA at room temperature for 1 hr. and probed with specific antibodies at 4°C overnight followed by secondary antibody anti-rabbit IgG, HRP-linked for 1 hr. at room temperature. Antibodies were obtained from Cell Signaling Technology except the β -actin antibody (Sigma-Aldrich). Blots were developed on film (Pierce Chemical) using ECL plus Western blotting substrate (Thermo Scientific).
NFκB reporter assays were performed in triplicates. Results were presented as mean ± standard deviation. Student’s t-test was used to find the significant differences between the means. The significant differences were reported as p < 0.05 (*) and p < 0.01 (**).
We thank Mark P Stevens (Institute of Animal Health, UK) for the BopE and SopE expression plasmids and Peter Cheung (Nanyang Technological University) and Liu Xinyu (NUS) for technical advice on the TAK1 immunoprecipitations and Western blots. This work is funded by the Ministry of Education Tier 2 grant T208A3105, the National Medical Research Council grant NMRC/EDG/1052/2011 to YHG, the Defense Threat Reduction Agency (HDTRA1-11-1-0003) to JFM, the Pacific Southwest Regional Center of Excellence in Biodefense and Emerging Infectious Diseases (U54 A1065359) to JFM, the National Science Foundation CBET 0853500, ECCS 0901154, DBI-0852701 awards, University of California Discovery Biotechnology Award 178517, the National Institutes of Health Roadmap for Medical Research Nanomedicine Initiative PN2EY018228, NIH R21EB014456, and an Innovator Award from the Broad Stem Cell Research Center at UCLA.
- Galyov EE, Brett PJ, DeShazer D: Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev Microbiol. 2010, 64: 495-517. 10.1146/annurev.micro.112408.134030.View ArticlePubMedGoogle Scholar
- Jones AL, Beveridge TJ, Woods DE: Intracellular survival of Burkholderia pseudomallei. Infect Immun. 1996, 64 (3): 782-790.PubMed CentralPubMedGoogle Scholar
- Wiersinga WJ, Currie BJ, Peacock SJ: Melioidosis. N Engl J Med. 2012, 367 (11): 1035-1044. 10.1056/NEJMra1204699.View ArticlePubMedGoogle Scholar
- Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ: Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol. 2006, 4 (4): 272-282. 10.1038/nrmicro1385.View ArticlePubMedGoogle Scholar
- Stevens MP, Haque A, Atkins T, Hill J, Wood MW, Easton A, Nelson M, Underwood-Fowler C, Titball RW, Bancroft GJ, Galyov EE: Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology. 2004, 150 (Pt 8): 2669-2676.View ArticlePubMedGoogle Scholar
- Warawa J, Woods DE: Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. FEMS Microbiol Lett. 2005, 242 (1): 101-108. 10.1016/j.femsle.2004.10.045.View ArticlePubMedGoogle Scholar
- Lee YH, Chen Y, Ouyang X, Gan YH: Identification of tomato plant as a novel host model for Burkholderia pseudomallei. BMC Microbiol. 2010, 10: 28-10.1186/1471-2180-10-28.PubMed CentralView ArticlePubMedGoogle Scholar
- Burtnick MN, Brett PJ, Nair V, Warawa JM, Woods DE, Gherardini FC: Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages. Infect Immun. 2008, 76 (7): 2991-3000. 10.1128/IAI.00263-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Stevens MP, Wood MW, Taylor LA, Monaghan P, Hawes P, Jones PW, Wallis TS, Galyov EE: An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol. 2002, 46 (3): 649-659. 10.1046/j.1365-2958.2002.03190.x.View ArticlePubMedGoogle Scholar
- Sun GW, Lu J, Pervaiz S, Cao WP, Gan YH: Caspase-1 dependent macrophage death induced by Burkholderia pseudomallei. Cell Microbiol. 2005, 7 (10): 1447-1458. 10.1111/j.1462-5822.2005.00569.x.View ArticlePubMedGoogle Scholar
- Miao EA, Mao DP, Yudkovsky N, Bonneau R, Lorang CG, Warren SE, Leaf IA, Aderem A: Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci U S A. 2010, 107 (7): 3076-3080. 10.1073/pnas.0913087107.PubMed CentralView ArticlePubMedGoogle Scholar
- Kwuan L, Adams W, Auerbuch V: Impact of host membrane pore formation by the Yersinia pseudotuberculosis type III secretion system on the macrophage innate immune response. Infect Immun. 2013, 81 (3): 905-914. 10.1128/IAI.01014-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Auerbuch V, Golenbock DT, Isberg RR: Innate immune recognition of Yersinia pseudotuberculosis type III secretion. PLoS Pathog. 2009, 5 (12): e1000686-10.1371/journal.ppat.1000686.PubMed CentralView ArticlePubMedGoogle Scholar
- Hapfelmeier S, Stecher B, Barthel M, Kremer M, Muller AJ, Heikenwalder M, Stallmach T, Hensel M, Pfeffer K, Akira S, Hardt WD: The Salmonella pathogenicity island (SPI)-2 and SPI-1 type III secretion systems allow Salmonella serovar typhimurium to trigger colitis via MyD88-dependent and MyD88-independent mechanisms. J Immunol. 2005, 174 (3): 1675-1685. 10.4049/jimmunol.174.3.1675.View ArticlePubMedGoogle Scholar
- Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, Tedin K, Taha MK, Labigne A, Zähringer U, Coyle AJ, DiStefano PS, Bertin J, Sansonetti PJ, Philpott DJ: Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science. 2003, 300 (5625): 1584-1587. 10.1126/science.1084677.View ArticlePubMedGoogle Scholar
- Zhao L, Kwon MJ, Huang S, Lee JY, Fukase K, Inohara N, Hwang DH: Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J Biol Chem. 2007, 282 (16): 11618-11628. 10.1074/jbc.M608644200.View ArticlePubMedGoogle Scholar
- Hii CS, Sun GW, Goh JW, Lu J, Stevens MP, Gan YH: Interleukin-8 induction by Burkholderia pseudomallei can occur without Toll-like receptor signaling but requires a functional type III secretion system. J Infect Dis. 2008, 197 (11): 1537-1547. 10.1086/587905.View ArticlePubMedGoogle Scholar
- Chen Y, Wong J, Sun GW, Liu Y, Tan GY, Gan YH: Regulation of type VI secretion system during Burkholderia pseudomallei infection. Infect Immun. 2011, 79 (8): 3064-3073. 10.1128/IAI.05148-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Sun GW, Gan YH: Unraveling type III secretion systems in the highly versatile Burkholderia pseudomallei. Trends Microbiol. 2010, 18 (12): 561-568. 10.1016/j.tim.2010.09.002.View ArticlePubMedGoogle Scholar
- Tan KS, Chen Y, Lim YC, Tan GY, Liu Y, Lim YT, Macary P, Gan YH: Suppression of host innate immune response by Burkholderia pseudomallei through the virulence factor TssM. J Immunol. 2010, 184 (9): 5160-5171. 10.4049/jimmunol.0902663.View ArticlePubMedGoogle Scholar
- Cullinane M, Gong L, Li X, Lazar-Adler N, Tra T, Wolvetang E, Prescott M, Boyce JD, Devenish RJ, Adler B: Stimulation of autophagy suppresses the intracellular survival of Burkholderia pseudomallei in mammalian cell lines. Autophagy. 2008, 4 (6): 744-753.View ArticlePubMedGoogle Scholar
- Muangman S, Korbsrisate S, Muangsombut V, Srinon V, Adler NL, Schroeder GN, Frankel G, Galyov EE: BopC is a type III secreted effector protein of Burkholderia pseudomallei. FEMS Microbiol Lett. 2011, 323 (1): 75-82. 10.1111/j.1574-6968.2011.02359.x.View ArticlePubMedGoogle Scholar
- Stevens MP, Friebel A, Taylor LA, Wood MW, Brown PJ, Hardt WD, Galyov EE: A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide exchange factor activity. J Bacteriol. 2003, 185 (16): 4992-4996. 10.1128/JB.185.16.4992-4996.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- French CT, Toesca IJ, Wu TH, Teslaa T, Beaty SM, Wong W, Liu M, Schroder I, Chiou PY, Teitell MA, Miller JF: Dissection of the Burkholderia intracellular life cycle using a photothermal nanoblade. Proc Natl Acad Sci U S A. 2011, 108 (29): 12095-12100. 10.1073/pnas.1107183108.PubMed CentralView ArticlePubMedGoogle Scholar
- Keestra AM, Winter MG, Auburger JJ, Frassle SP, Xavier MN, Winter SE, Kim A, Poon V, Ravesloot MM, Waldenmaier JF, Tsolis RM, Eigenheer RA, Bäumler AJ: Manipulation of small Rho GTPases is a pathogen-induced process detected by NOD1. Nature. 2013, 496 (7444): 233-237. 10.1038/nature12025.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu TH, Teslaa T, Kalim S, French CT, Moghadam S, Wall R, Miller JF, Witte ON, Teitell MA, Chiou PY: Photothermal nanoblade for large cargo delivery into mammalian cells. Anal Chem. 2011, 83 (4): 1321-1327. 10.1021/ac102532w.PubMed CentralView ArticlePubMedGoogle Scholar
- Haraga A, West TE, Brittnacher MJ, Skerrett SJ, Miller SI: Burkholderia thailandensis as a model system for the study of the virulence-associated type III secretion system of Burkholderia pseudomallei. Infect Immun. 2008, 76 (11): 5402-5411. 10.1128/IAI.00626-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Dai L, Aye Thu C, Liu XY, Xi J, Cheung PC: TAK1, more than just innate immunity. IUBMB Life. 2012, 64 (10): 825-834. 10.1002/iub.1078.View ArticlePubMedGoogle Scholar
- Abu-Zant A, Jones S, Asare R, Suttles J, Price C, Graham J, Kwaik YA: Anti-apoptotic signalling by the Dot/Icm secretion system of L. pneumophila. Cell Microbiol. 2007, 9 (1): 246-264. 10.1111/j.1462-5822.2006.00785.x.View ArticlePubMedGoogle Scholar
- Bartfeld S, Engels C, Bauer B, Aurass P, Flieger A, Bruggemann H, Meyer TF: Temporal resolution of two-tracked NF-kappaB activation by Legionella pneumophila. Cell Microbiol. 2009, 11 (11): 1638-1651. 10.1111/j.1462-5822.2009.01354.x.View ArticlePubMedGoogle Scholar
- Losick VP, Isberg RR: NF-kappaB translocation prevents host cell death after low-dose challenge by Legionella pneumophila. J Exp Med. 2006, 203 (9): 2177-2189. 10.1084/jem.20060766.PubMed CentralView ArticlePubMedGoogle Scholar
- Shin S, Case CL, Archer KA, Nogueira CV, Kobayashi KS, Flavell RA, Roy CR, Zamboni DS: Type IV secretion-dependent activation of host MAP kinases induces an increased proinflammatory cytokine response to Legionella pneumophila. PLoS Pathog. 2008, 4 (11): e1000220-10.1371/journal.ppat.1000220.PubMed CentralView ArticlePubMedGoogle Scholar
- Losick VP, Haenssler E, Moy MY, Isberg RR: LnaB: a Legionella pneumophila activator of NF-kappaB. Cell Microbiol. 2010, 12 (8): 1083-1097. 10.1111/j.1462-5822.2010.01452.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Ge J, Xu H, Li T, Zhou Y, Zhang Z, Li S, Liu L, Shao F: A Legionella type IV effector activates the NF-kappaB pathway by phosphorylating the IkappaB family of inhibitors. Proc Natl Acad Sci U S A. 2009, 106 (33): 13725-13730. 10.1073/pnas.0907200106.PubMed CentralView ArticlePubMedGoogle Scholar
- Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, Bertin J, DiStefano PS, Yaniv M, Sansonetti PJ, Philpott DJ: CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep. 2001, 2 (8): 736-742. 10.1093/embo-reports/kve155.PubMed CentralView ArticlePubMedGoogle Scholar
- Bruno VM, Hannemann S, Lara-Tejero M, Flavell RA, Kleinstein SH, Galan JE: Salmonella Typhimurium type III secretion effectors stimulate innate immune responses in cultured epithelial cells. PLoS Pathog. 2009, 5 (8): e1000538-10.1371/journal.ppat.1000538.PubMed CentralView ArticlePubMedGoogle Scholar
- Keestra AM, Winter MG, Klein-Douwel D, Xavier MN, Winter SE, Kim A, Tsolis RM, Baumler AJ: A Salmonella virulence factor activates the NOD1/NOD2 signaling pathway. MBio. 2011, 2 (6): e00266-11-PubMedGoogle Scholar
- Pudla M, Kananurak A, Limposuwan K, Sirisinha S, Utaisincharoen P: Nucleotide-binding oligomerization domain-containing protein 2 regulates suppressor of cytokine signaling 3 expression in Burkholderia pseudomallei-infected mouse macrophage cell line RAW 264.7. Innate Immun. 2011, 17 (6): 532-540. 10.1177/1753425910385484.View ArticlePubMedGoogle Scholar
- Myers ND, Chantratita N, Berrington WR, Chierakul W, Limmathurotsakul D, Wuthiekanun V, Robertson JD, Liggitt HD, Peacock SJ, Skerrett SJ, West TE: The Role of NOD2 in Murine and Human Melioidosis. J Immunol. 2014, 192 (1): 300-307. 10.4049/jimmunol.1301436.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu B, Koo GC, Yap EH, Chua KL, Gan YH: Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect Immun. 2002, 70 (2): 504-511. 10.1128/IAI.70.2.504-511.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Brett PJ, DeShazer D, Woods DE: Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol. 1998, 48 (Pt 1): 317-320.View ArticlePubMedGoogle Scholar
- Schafer A, Tauch A, Jager W, Kalinowski J, Thierbach G, Puhler A: Small mobilizable multi-purpose cloning vectors derived from the Escherichia coli plasmids pK18 and pK19: selection of defined deletions in the chromosome of Corynebacterium glutamicum. Gene. 1994, 145 (1): 69-73. 10.1016/0378-1119(94)90324-7.View ArticlePubMedGoogle Scholar
- Choi KH, Mima T, Casart Y, Rholl D, Kumar A, Beacham IR, Schweizer HP: Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl Environ Microbiol. 2008, 74 (4): 1064-1075. 10.1128/AEM.02430-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY: Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol. 2008, 172 (5): 1174-1183. 10.2353/ajpath.2008.070762.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.